Podcast appearances and mentions of ira pastor

Send us a Text Message.Dr. William Padula, PhD, MS, MSc, is Assistant Professor, Pharmaceutical & Health Economics and Fellow, Schaeffer Center for Health Policy & Economics, at the Alfred E. Mann School of Pharmacy & Pharmaceutical Sciences, University of Southern California ( https://healthpolicy.usc.edu/author/william-padula-phd/ ). His research explores the theoretical foundations of medical cost-effectiveness analysis, especially pertaining to issues around the value of vaccines, healthcare delivery and patient safety in hospitals for acquired conditions such as pressure injuries. He has received grant funding in the form of a Career Development Award from the National Institutes of Health (NIH), the Bill & Melinda Gates Foundation, and the PhRMA Foundation Frontier Award. He has authored 100+ scientific papers, letters and book chapters that have been published in leading medical, economic, and health policy journals. Dr. Padula is also Co-Founder & Principal of Stage Analytics ( https://stageanalytics.com/william-v-padula-phd/ ), a consulting firm that is committed to providing the highest quality of scientific solutions to advance health care. Dr. Padula is an Associate Editor of Value in Health, and serves on the editorial boards of Applied Health Economics and Health Policy and Journal of Clinical Nursing. His work has been featured in the New York Times, The Atlantic, The Hill, Forbes and other media. He is a past recipient of the Award for Excellence in Health Economics and Outcomes Research from the International Society of Pharmacoeconomics and Outcomes Research (ISPOR); the Academy Health Outstanding Dissertation Award; and the Society for Advancement in Wound Care (SAWC) Young Investigator Award. He served as President for the U.S. National Pressure Injury Advisory Panel (NPIAP) from 2021-2022. He was also Commissioner for the American Nurses Credentialing Center (ANCC) Magnet® Recognition Program from 2016-2019. Dr. Padula has previously held appointments as an Assistant Professor at the Johns Hopkins Bloomberg School of Public Health in Baltimore, USA, and as a postdoctoral fellow at The University of Chicago. He was a visiting scholar at the University of York Centre for Health Economics in York, UK, the Oxford Institute for Nursing, Midwifery and Allied Health in Oxford, UK, and the University of Technology Sydney in Sydney, Australia. He received his B.S. in Chemical Engineering from Northwestern University, M.S. in Evaluative Clinical Science from Dartmouth College, M.S. in Data Analytics from University of Chicago, and Ph.D. in Pharmaceutical Economics from University of Colorado. #HealthEconomics #USC #WoundCare #Pharmacy #PressureSores #Pharmaceuticals #WilliamPadula #HealthcareValue #Outcomes #WastefulSpending #Medicare #Medicaid #progresspotentialandpossibilities #IraPastor #podcast #podcaster #viralpodcast #STEM #Innovation #Technology #Science #Research Support the Show.

¡Bienvenido al canal oficial de YouTube: Iglesia Nueva Vida, Una iglesia para hoy! En este canal, encontrará una variedad de contenido para fortalecer su fe: mensajes de nuestros diversos predicadores, canciones de alabanza de nuestro equipo de NV Worship, ¡y más! Nuestra pasión es conectar a las personas con Dios, una persona a la vez. ¡Únase a nuestras reuniones en línea todos los sabados desde las 6h30 p.m, para experimentar la presencia de Dios con miles de otros creyentes! --- MANTENTE CONECTADO ! Sitio Web: https://nouvellevie.com/vie-deglise/nueva-vida/ Facebook: https://www.facebook.com/nuevavidainv Instagram: https://www.instagram.com/nuevavidainv ESCÚCHANOS (PODCAST) iTunes Podcast ; http://bit.ly/iTunesinv Spotify : http://bit.ly/Spotifyinv SoundCloud : http://bit.ly/Soundcloudinv #IglesiaNuevaVida @invmontreal

Ira Pastor - Chief Executive Officer – Bioquark Inc. (www.bioquark.com) - Over 30 years of experience across multiple sectors of the pharmaceutical industry including pharmaceutical commercialization, biotech drug development, managed care, distribution, OTC, and retail; Served as VP, Business Development for drug development company Phytomedics Inc., raising $40 million of private equity, consummating over $50 million of licensing deals, and bringing lead drug candidate from discovery stage to Phase III development; Prior to that, employed by SmithKline Beecham Pharmaceuticals working in sales, marketing, and business strategy positions. Mr. Pastor has also served as Vice President of Corporate Development for the pharmacy benefit management company Prescription Delivery Systems (acquired by Cigna Health Insurance); MBA, Temple University; BS, Pharmacy, Rutgers University; He is also a Board Member of RegenerAge SAPI de CV, (www.regenerage.clinic/en/) a clinical company focused on expedited translational therapeutic applications of regenerative and rejuvenative healthcare interventions, the Reanima Project (http://www.reanima.tech), member of the Executive Council of the World Academy of Medical Science – WAMS (https://wams.online/our_team/ira-s-pastor/), and member of the World Economic Forum's Human Enhancement council (https://www.weforum.org/people/ira-pastor).

Ira Pastor - Chief Executive Officer – Bioquark Inc. (www.bioquark.com) - Over 30 years of experience across multiple sectors of the pharmaceutical industry including pharmaceutical commercialization, biotech drug development, managed care, distribution, OTC, and retail; Served as VP, Business Development for drug development company Phytomedics Inc., raising $40 million of private equity, consummating over $50 million of licensing deals, and bringing lead drug candidate from discovery stage to Phase III development; Prior to that, employed by SmithKline Beecham Pharmaceuticals working in sales, marketing, and business strategy positions. Mr. Pastor has also served as Vice President of Corporate Development for the pharmacy benefit management company Prescription Delivery Systems (acquired by Cigna Health Insurance); MBA, Temple University; BS, Pharmacy, Rutgers University; He is also a Board Member of RegenerAge SAPI de CV, (www.regenerage.clinic/en/) a clinical company focused on expedited translational therapeutic applications of regenerative and rejuvenative healthcare interventions, the Reanima Project (http://www.reanima.tech), member of the Executive Council of the World Academy of Medical Science – WAMS (https://wams.online/our_team/ira-s-pastor/), and member of the World Economic Forum's Human Enhancement council (https://www.weforum.org/people/ira-pastor).

Iris Van der Veken is Executive Director and Board Member of the Responsible Jewellery Council (https://www.responsiblejewellery.com), the world's leading standard setting organization for the jewellery industry, promoting standards that underpin people's trust in the worldwide jewellery. Responsible Jewellery Council was founded in 2005 by 14 member organizations including: ABN AMRO, BHP Billiton Diamonds, Cartier, World Jewellery Confederation, Diamond Trading Company (part of De Beers), Diarough, Jewelers of America, National Association of Goldsmiths (UK), Newmont Mining, Rio Tinto, Rosy Blue, Signet Group, Tiffany & Co., and Zale Corporation. With a University of Antwerp Bachelor of Law, Iris is a coalition-builder with over 20 years global experience of working in technology, diamonds and jewelry, fashion and government. Iris was actively involved in the development of the Responsible Jewellery Council (RJC) Code of Practices, and managed the first global RJC pilot audit in partnership with SGS - the world's leading inspection, verification, testing and certification company. Iris is also a board member of Diamonds Do Good (https://www.diamondsdogood.com), a global nonprofit organization whose mission is supporting programs that develop and empower people in natural diamond communities and sharing these stories of positive impact. Iris established and chaired the Network of the United Nations Global Compact Belgium in partnership with the Belgian Ministry of Foreign Affairs, Foreign Trade and Development Cooperation, chaired the consultative and advisory body to the Office of the Children's Rights Commissioner in Flanders, and was honored by the Minister of Foreign Affairs, Foreign Trade and European Affairs of Belgium for initiating the Global Compact and for her work on promoting corporate social responsibility with a focus on human rights including children's rights and the role of business.

Dr. Satchidananda ("Satchin") Panda, is Professor, Regulatory Biology Laboratory, and Rita and Richard Atkinson Chair, at the Salk Institute for Biological Studies, La Jolla, California (https://www.salk.edu/scientist/satchidananda-panda/), where his research focuses on the circadian regulation of behavior, physiology and metabolism in model organisms and in humans. Dr. Panda is also a founding executive member of the Center for Circadian Biology at the University of California, San Diego (https://ccb.ucsd.edu/). With a PhD from The Scripps Research Institute, La Jolla, California, and his postdoctoral research at the Genomics Institute of the Novartis Research Foundation, San Diego, Dr. Panda's laboratory is interested in understanding the molecular mechanisms of this biological clock (or circadian oscillator), which in most organisms coordinates behavior and physiology with the natural light-dark cycle. Among Dr. Panda's discoveries include a blue-light sensing cell type in the retina which entrains our master circadian clock, affects mood, and regulates the production of sleep hormone melatonin, as well as his discovery that maintaining a daily feeding-fasting cycle – popularly known as Time-restricted feeding (TRF) – can prevent and reverse metabolic diseases. Based on a feasibility study in humans, his lab is currently carrying out a smartphone based study (www.mycircadianclock.org) to assess the extent of circadian disruption among adults. Dr. Panda's laboratory uses genetic, genomics and biochemical approaches to identify genes under circadian regulation in different organs and to understand the mechanisms of such regulation. Dr. Panda is also a Pew Biomedical Scholar, a recipient of the Julie Martin Mid-Career Award in Aging Research, is extensively published in the scientific literature, and is also the author of the books: The Circadian Code: Lose Weight, Supercharge Your Energy, and Transform Your Health from Morning to Midnight and The Circadian Diabetes Code: Discover the Right Time to Eat, Sleep, and Exercise to Prevent and Reverse Prediabetes and Diabetes.

Dr. Steven Austad (https://www.stevenaustad.com/) is Distinguished Professor and Protective Life Endowed Chair in Healthy Aging Research, Department of Biology, University of Alabama at Birmingham (UAB), and Scientific Director of the American Federation for Aging Research (https://www.uab.edu/cas/biology/people/faculty/steven-n-austad). In addition, Dr. Austad directs the NIH-supported UAB Nathan Shock Center of Excellence in the Basic Biology of Aging, one of only six such Centers in the United States, is the Co-Director of the Nathan Shock Centers Coordinating Center, and serves on the Executive Committee of the National Institute on Aging's Research Centers Collaborative Network. Dr. Austad is a fellow of the American Association for the Advancement of Science, the Gerontological Society of America and has received multiple prestigious awards for his research work. Dr. Austad's current research seeks to understand the underlying causes of aging with a long-term goal of developing medical interventions that slow the age-related decay in human health. Dr. Austad is the author of more than 200 scientific peer-reviewed publications covering nearly every aspect of aging from cells to societies, is the author of the book "Why We Age: What Science Is Discovering about the Body's Journey Through Life", and his new book on the natural history of exceptional longevity, "Methuselah's Zoo - What Nature Can Teach Us About Living Longer, Healthier Lives", will be coming out in April of 2022. Dr. Austad has a B.A. from UCLA in English Literature, a B.S. from California State University, Northridge in Biology, and a Ph.D. from Purdue University, in Biological Sciences.

Dr. Bryon Bhagwandin, PhD is Co-Founder and CEO at Recalibrate Solutions (https://www.recalibratesolutions.com/), a company that is focused on empowering physicians to eliminate toxic stress from the lives of children, by monitoring stress system development, with a novel 5-minute, disposable, saliva cortisol test. Dr. Bhagwandin has served as an executive for multiple start-up companies, has spent more than 20 years in medical product development, and possesses a unique combination of technical expertise, leadership, and business acumen. Dr. Bhagwandin has as BS in Physics from Indiana University Bloomington, an MS in physics from Purdue University, and a PhD in biomedical engineering from University of Washington, and has led multiple product development teams, successfully creating diagnostic, therapeutic, and drug-device combination products. Dr. Bhagwandin has a complex understanding of the unique business challenges that must be navigated by medical device companies including experience in design-controls, quality-system compliance, internal review boards, clinical testing, regulatory submissions, insurance codes, reimbursement models, hospital purchasing-cycles, and marketing through scientific research and peer review publications – a truly unique skill set.

Dr. Gladys Kalema-Zikusoka, is the Founder and CEO of Conservation Through Public Health (CTPH - https://ctph.org/), a 16-year old non-profit organization, based in Uganda, that promotes conservation by improving the quality of life of people and wildlife to enable them to coexist in and around protected areas in Africa, and she has become one of the leading conservationists and scientists working to save the critically endangered mountain gorillas of East Africa. Dr. Kalema-Zikusoka is also on the Scientific Advisory Group for the Origins of Novel Pathogens (SAGO) of the World Health Organization (https://www.who.int/groups/scientific-advisory-group-on-the-origins-of-novel-pathogens-(sago)/about) Dr. Kalema-Zikusoka trained as a veterinarian at the University of London's Royal Veterinary College. Between 1996 and 2000, she set up the first Veterinary Unit at the Uganda Wildlife Authority. From 2000 to 2003, she completed a zoological medicine residency and masters in specialized veterinary medicine at North Carolina State University and North Carolina Zoological Park. Dr. Kalema-Zikusoka became an Ashoka Fellow in 2007 for merging Uganda's wildlife management and rural public health programs to create common resources for both people and animals. Prior to setting up CTPH, Dr. Kalema-Zikusoka also did a certificate in Non-profit management from Duke University. Most recently in 2016, she completed an MBA in Global Business and Sustainability – Social Entrepreneurship Track. Dr. Kalema-Zikusoka's most recent awards include the 2017 World Wildlife Day Award from the Ministry of Tourism, Wildlife and Antiquities (MTWA) for outstanding contribution to conservation in Uganda and 2017 Golden Jubilee Award from the President of Uganda for distinguished service to the nation as a veterinarian and conservationist on International Women's Day. Other awards include San Diego Zoo's 2008 “Conservation in Action Award,” the 2009 Whitley Gold Award for outstanding leadership in grassroots nature conservation; 2011 Wings World Quest Women of Discovery Humanitarian Award, and 2014 CEO Communications Africa's Most Influential Women in Business and Government Award in Medicine and Veterinary category. Under Dr. Kalema-Zikusoka's leadership, Conservation Through Public Health won the Global Development Network 2012 Japanese Most Innovative Development Project Award for scaling social service delivery. Dr. Kalema-Zikusoka recently became a National Geographic Explorer and winner of the Sierra Club's 2018 EarthCare Award, 2019 Finalist for the Tusk Award for Conservation in Africa, the 2020 Uganda Veterinary Association World Veterinary Day Award and the 2020 Aldo Leopold award. She is also on the leadership council of Women for the Environment in Africa.

Dr. Madelyn Fernstrom, PhD, CNS (https://drmadelynfernstrom.com/) is a neuroscientist, clinician, health strategist, and NBC broadcast journalist, who serves as Professor of Psychiatry, Epidemiology and Surgery at the University of Pittsburgh School of Medicine, Founding Director of the UPMC Weight Management Center, Director of the Community Pediatric Weight Management Program for UPMC Children's Hospital of Pittsburgh, and Senior Advisor, Health Management, UPMC Health Plan. Dr. Fernstrom earned her B.A. in Biology from Boston University, her PhD. in nutritional biochemistry, metabolism and neuropharmacology from Massachusetts Institute of Technology (MIT), and did her Post-Doctoral Fellowship, in endocrinology, metabolism, and behavior at Harvard Medical School, and also is a board-certified nutrition specialist from the American College of Nutrition. Dr. Fernstrom is nationally known for the creation and implementation of scalable health initiatives supporting patients, providers, payors, and employers and her work has focused on developing impactful platforms supporting the physical and emotional needs of the healthy, acutely or chronically ill, and aging populations, as well as the needs of those who care for them. Dr. Fernstrom has published more than 100 original research articles, as well as three books, including The Real You Diet: Your Personal Program for Lasting Weight Loss, Don't Eat This If You're Taking That: The Hidden Risks of Mixing Food and Medicine, and Runner's World The Runner's Diet: The Ultimate Eating Plan That Will Make Every Runner (and Walker) Leaner, Faster, and Fitter. In addition, Dr. Fernstrom is the on-air NBC News Health Editor, a contributor to several NBC News digital platforms, and serves as the Chief Clinical and Science Advisor for Philadelphia headquartered Quil (https://quilhealth.com/), the joint venture of Independence Health Group and Comcast, creating digital health platforms that offers personalized and interactive health journeys to consumers and their caregivers.

Jiren Parikh is the President & CEO of Ghost Robotics (https://www.ghostrobotics.io/), a Philadelphia-based company developing agile, all-weather, unstoppable, autonomous 4-leg robots (also known as Quadrupedal Unmanned Ground Vehicles, or Q-UGVs) which offer superior operability over wheeled and tracked devices on unstructured terrain in rough and demanding environments. Q-UGVs now have a place in a broad range of government and enterprise applications where mobile robots with four legs have inherent advantages over wheels, tracks and even bipedal systems. Q-UGVs can not only manage unstructured terrain well but are built for demanding customers in demanding environments including military, homeland, industrial, energy & mining markets, and as such have the ability to keep humans and K9s out of harm's way. Jiren is an entrepreneurial leader with 25-years experience building, leading, and turning around technology businesses, and growth functions. Jiren has served a variety of roles during his career including as CEO, COO, CFO, Business Unit Head, and functional leader of business and corporate development, sales, marketing and product management, as well as in board, advisory, interim executive and consulting roles, primarily at early and growth companies, involved in marketing software, SaaS and platforms, mobile and IoT applications, subscription services, digital content, and now robotics.

Currently the global beauty industry represents a US$500 billion market, and makeup represents about US$100 billion of that total. Millions of women rely on beauty tutorials for makeup ideas and beauty tips, but find it challenging to recreate professional makeup looks, as they are following makeup application instructions for faces that do not look like their own. As a result, they are not getting their best makeup look, and they are being forced to compare themselves to other women, impacting their confidence. Jennifer Christenson, is the Founder & CEO of FaceTrace Inc. (https://www.facetracebeauty.com/), an innovative company with a novel mobile app that uses proprietary technologies, including augmented reality, to guide women and beauty lovers in properly applying cosmetics without having to visit an in-store beauty counter, hire a professional makeup artist, or attempt to follow online makeup tutorials. Jennifer is also Co-Founder and CEO of JMP Global, which works in the areas of digital media, social networking, and event creation and management. Jennifer has her undergraduate degree from University of Michigan in Psychology / PreMed, has been a producer / host of several Chicago area television shows, was a Miss Illinois USA 2012 First Runner Up & Humanitarian Award Recipient, and is an accomplished author of the book Real by Jennifer Christenson.

Dr. Patrick van der Smagt is Director of ArtificiaI Intelligence Research, Volkswagen AG, and Head of Argmax.AI (https://argmax.ai/), the Volkswagen Group Machine Learning Research Lab, in Munich, focusing on a range of research domains, including probabilistic deep learning for time series modelling, optimal control, reinforcement learning robotics, and quantum machine learning. Dr. van der Smagt is also a research professor in the Computer Science faculty at Eötvös Loránd University in Budapest. Dr. van der Smagt previously directed a lab as professor for machine learning and biomimetic robotics at the Technical University of Munich while leading the machine learning group at the research institute fortiss, and before that, founded and headed the Assistive Robotics and Bionics Lab at DLR, the German Aerospace Center. Besides publishing numerous papers and patents on machine learning, robotics, and motor control, Dr. van der Smagt has won a number of awards, including the 2013 Helmholtz-Association Erwin Schrödinger Award, the 2014 King-Sun Fu Memorial Award, the 2013 Harvard Medical School/MGH Martin Research Prize, the 2018 Webit Best Implementation of AI Award, and best-paper awards at various machine learning and robotics conferences and journals. Dr. van der Smagt also serves as a scientific reviewer for governmental funding organizations and served on various conference and journal boards. Dr. van der Smagt is founding chairman of a non-for-profit organization for Assistive Robotics for tetraplegics, and co-founder of various tech companies. In 2018, he started a for-good initiative called 10-to-GO (https://10togo.eu/), by supporting teams using machine learning for the United Nations Sustainable Development Goals. Also then, he initiated etami (https://www.etami.eu/en.html), an initiative on Ethical and Trustworthy Artificial and Machine Intelligence, creating an organization with almost 20 multinationals and universities. Dr. van der Smagt has his Master of Science (M.Sc.), Computer Science from Vrije Universiteit Amsterdam, and his Doctor of Philosophy (Ph.D.), Computer and Information Sciences, from University of Amsterdam.

Ben Novak is Lead Scientist, at Revive & Restore (https://reviverestore.org/), a California-based non-profit that works to bring biotechnology to conservation biology with the mission to enhance biodiversity through the genetic rescue of endangered and extinct animals . Ben collaboratively pioneers new tools for genetic rescue and de-extinction, helps shape the genetic rescue efforts of Revive & Restore, and leads its flagship project, The Great Passenger Pigeon Comeback, working with collaborators and partners to restore the ecology of the Passenger Pigeon to the eastern North American forests. Ben uses his training in ecology and ancient-DNA lab work to contribute, hands-on, to the sequencing of the extinct Passenger Pigeon genome and to study important aspects of its natural history .  Ben's mission in leading the Great Passenger Pigeon Comeback is to set the standard for de-extinction protocols and considerations in the lab and field. His 2018 review article, “De-extinction,” in the journal Genes, helped to define this new term. More recently, his treatment, "Building Ethical De-Extinction Programs—Considerations of Animal Welfare in Genetic Rescue" was published in December 2019 in The Routledge Handbook of Animal Ethics: 1st Edition. Ben's work at Revive & Restore also includes extensive education and outreach, the co-convening of seminal workshops, and helping to develop the Avian and Black-footed Ferret Genetic Rescue programs included in the Revive & Restore Catalyst Science Fund. Ben graduated from Montana State University studying Ecology and Evolution. He later trained in Paleogenomics at the McMaster University Ancient DNA Centre in Ontario. This is where he began his study of passenger pigeon DNA, which then contributed to his Master's thesis in Ecology and Evolutionary Biology at the University of California Santa Cruz. This work also formed the foundational science for de-extinction. Ben also worked at the Australian Animal Health Laboratory–CSIRO (Commonwealth Scientific and Industrial Research Organisation) to advance genetic engineering protocols for the pigeon.

 Ms. Bayan Abusalameh is a 2020/2021 Chevening Scholar in Advanced Mechanical Engineering, at Queen Mary University of London (QMUL), who just finished off her Master's Dissertation entitled “An Innovative Structural Design For a 1U CubeSat” (The Palestine-1) Ms. Abusalameh is also a member of the Institution of Mechanical Engineers Unmanned Aerial System (UAS) team of QMUL. Ms. Abusalameh has her Bachelor's Degree in Mechanical Engineering from Birzeit University and her MSC in Advanced Mechanical Engineering from Queen Mary University of London. 

Mati Gill is the Chief Executive Officer, of AION Labs (https://aionlabs.com/), a company recently launched and backed by a coalition of pharma and tech leaders, including AstraZeneca, Merck, Pfizer, Teva, Amazon Web Services (AWS), and the Israel Biotech Fund (IBF) and Israel Innovation Authority, to improve the whole drug discovery & drug development process with AI and computational biology. Mati has an MBA (Healthcare & Innovation) and BS degree in law from Reichman University / IDC Herzliya, and has over a decade of experience in leadership roles in the biopharma industry, including most recently as Head of Government Affairs, Corporate & International Markets, at Teva Pharmaceuticals. Mati also spent 4 years as Member Of The Board Of Advisors and Directors, at Sanara Ventures, a healthcare investment platform backed by Philips & Teva, providing Pre-seed, Seed and A round financing to young companies. Prior to Teva, Mati was Chief of Staff to Israel's Minister of Public Security.

 H.E. Dr. Sara Al Madani (https://www.sara-almadani.com/), is a well-known entrepreneur, advocate for women, fashion designer, brand ambassador, social media personality, and has served as a board member of the UAE Ministry of Economy's SME Projects and Enterprise Council, Board Member of the Sharjah Economic Excellence Network, and board member of the Sharjah Chamber of Commerce and Industry (selected by His Highness Sheikh Dr Sultan Bin Mohammed Al Qassimi, sovereign ruler of the Emirate of Sharjah, UAE) making her the youngest member of their board. Sara's parents inspired her to start her own business at a young age. She set up her own fashion brand at 15 with the aim of changing how Arab women dress, and her unique, modern take on the abaya has attracted fans across the Middle East and Africa. Following her success as a young entrepreneur and business woman, Sara was selected to participate on the aforementioned government boards, to inspire more women in the UAE to become entrepreneurs, and has become a sought after and honored speaker in many universities, colleges and institutes. Sara's business portfolio has included, but is not limited to: Founder & Owner of Rouge Couture (now known as Sara Al Madani Fashion Design); Owner / Partner in Shabarbush restaurant; Owner of Social Fish innovative idea consultancy; Co-Founder and CEO, HalaHi, the region's first celebrity shout-out platform; and Co-Founder, Proposal Cupids. Sara is also Middle East Brand Ambassador for many companies, including Nivea, Natura Bisse, and Mercedes. 

Dr. Ann Marie Kimball  is a physician, epidemiologist and currently holds the roles of Associate Fellow at the international affairs think tank Chatham House, and Vice Chair, COVID 19 task force, at The Rotary Foundation / Rotary International. Previously, Dr. Kimball served as a strategic advisor to the Rockefeller Foundation, supporting the strengthening and development of strategies for Ebola, post-Ebola, and health crisis response, including planning and guiding the formation of a regional disease surveillance network in collaboration with Connecting Organizations for Regional Disease Surveillance (CORDS). Before joining the Rockefeller Foundation, Dr. Kimball served as technical and strategic lead for the Bill and Melinda Gates Foundation surveillance strategy formation. Prior to Gates, Dr. Kimball served as Professor of Epidemiology for the University of Washington (UW), School of Public Health, with adjunct appointments in Medicine (Bioinformatics and Infectious Diseases) and the Jackson School of Foreign Affairs. During her tenure at UW, Dr. Kimball founded and directed the APEC Emerging Infections Network, and led research and training programs in Surveillance and Informatics in Peru and Thailand. Dr. Kimball's research focus on global trade and emerging infections earned her a Fulbright New Century Scholars award and a Guggenheim Scholars award. Dr. Kimball is also the author of Risky Trade: Infectious Diseases in an Era of Global Trade, which was highly reviewed by NEJM, Emerging Infections and Lancet. She has authored numerous scientific publications, and served on numerous Institute of Medicine panels. She is also a fellow in the American College of Preventive Medicine and member of the National Biosurveillance Advisory group (NBAS) from the Centers for Disease Control. Dr. Kimball is a former Epidemic Intelligence Service Officer for the Centers for Disease Control in Atlanta, and has worked and lived in the Yemen Arab Republic, Ivory Coast, and Senegal. She served as Director of National Program Support for Pan American Health Organization, directing the elaboration and implementation of medium term AIDS plans in member countries throughout Latin America and the Caribbean. She also served as Director of HIV/AIDS for Washington State, and the founding Chair of the National Alliance of State and Territorial AIDS Directors (NASTAD) in the United States. She attended on staff at Harborview Medical Center first on HIV/AIDS (10 years), then the International Clinic (7 years) and finally UW/Seattle King County at Harborview Medical Center as an attending at the STD clinic.

Joanna Bensz is Founder and CEO of Longevity Center (https://longevity-center.eu/), a boutique preventive health and longevity medical center, that focuses on scientifically and medically advanced technologies and protocols for healthy longevity and sustainable health. Joanna is also Founder and CEO of the International Institute of Longevity (IIOL - https://l-institute.com/), an international organization with offices in Liechtenstein and Poland, co-founded in partnership with H.S.H. Prince Michael of Liechtenstein, focusing on developing a healthy longevity agenda in Europe, identifying, highlighting and promoting solutions, technologies and lifestyle choices that prevent chronic and age related diseases leading to increasing vitality and healthy life spans. Over her career, Joanna has spent time in a range of regional, general and business development director positions, with a number of Fortune 500 companies across Central and Eastern Europe, including at the international project management, architectural and engineering PM Group, Lockheed Martin, and at Geopolitical Intelligence Services, an organization providing independent political intelligence, strategic analysis and future scenarios to companies, governments, organizations and individual leaders, also founded by H.S.H. Prince Michael of Liechtenstein. Joanna has also served as the Vice Chairman and Board Member of the American Chamber of Commerce in Poland, and was responsible for development and leadership of AmCham regional offices in Wroclaw and Kraków. Joanna holds a Master of Arts degree in German Studies from University in Wroclaw, as well as a Diploma in Strategic and International Marketing at the Dublin Business School. She also completed the Advanced Management Program at IESE, University of Navarra in Barcelona.

Mike Graglia is the Managing Director & Co-Founder of the SynGAP Research Fund (SRF - https://www.syngapresearchfund.org/), an organization that he set up in 2018 with his wife Ashley, after their son was diagnosed with a rare neurological disease caused by an insufficiency in SynGAP protein, which causes the life-changing diagnoses of Epilepsy, Autism, sleep disorder and intellectual disability. The mission of SRF is to improve the quality of life of SynGAP1 patients through the research and development of treatments, therapies and support systems. Previously, Mike worked at the Emerson Collective, New America Foundation, the Bill and Melinda Gates Foundation, BCG, the World Bank/IFC and the US Peace Corps/Namibia. During his time in Africa he created a small charity to fund girls' education. Mike graduated from Gonzaga University with a BS in mathematics. He then attended the Johns Hopkins School of Advanced International Studies (SAIS) and Columbia Business School.

Dr. Paul A. Offit, MD, (https://www.paul-offit.com/) is an internationally recognized expert in the fields of virology and immunology, Co-Inventor of a landmark vaccine for the prevention of Rotavirus gastroenteritis, and holds multiple titles including - Director of the Vaccine Education Center at Children's Hospital Of Philadelphia (CHOP), Maurice R. Hilleman Chair of Vaccinology and Professor of Pediatrics, Perelmann School of Medicine, University of Pennsylvania, and Adjunct Associate Professor, The Wistar Institute of Anatomy and Biology. Dr. Offit was a member of the Advisory Committee on Immunization Practices to the Centers for Disease Control and Prevention, a founding advisory board member of the Autism Science Foundation and the Foundation for Vaccine Research, a member of the Institute of Medicine, and co-editor of the foremost vaccine text, Vaccines. Dr. Offit is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, a Research Career Development Award from the National Institutes of Health, and the Sabin Vaccine Institute Gold Medal. Dr. Offit has published more than 150 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of a landmark rotavirus vaccine recommended for universal use in infants by the CDC. For this achievement, Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases, and was honored by Bill and Melinda Gates during the launch of their Foundation's Living Proof Project for global health. In addition, he has received numerous other awards and honors for his groundbreaking work. Dr. Offit is also an author of many books including, but not limited to: Vaccinated: One Man's Quest to Defeat the World's Deadliest Diseases, Overkill: When Modern Medicine Goes Too Far, The Cutter Incident: How America's First Polio Vaccine Led to the Growing Vaccine Crisis, Breaking the Antibiotic Habit, Do You Believe in Magic, and his most recent, You Bet Your Life: From Blood Transfusions to Mass Vaccination, the Long and Risky History of Medical Innovation.

Dr. Morgan Levine, PhD (https://www.morganlevinelab.com/) is Assistant Professor of Pathology and Epidemiology, at the Yale School of Medicine. Dr. Levine is also a member of both the Yale Combined Program in Computational Biology and Bioinformatics, and the Yale Center for Research on Aging. Her work relies on an interdisciplinary approach, integrating theories and methods from statistical genetics, computational biology, and mathematical demography to develop biomarkers of aging for humans and animal models using high-dimensional -omics data. As PI or co-Investigator on multiple NIH-, Foundation-, and University-funded projects, she has extensive experience using systems-level and machine learning approaches to track epigenetic, transcriptomic, and proteomic changes with aging and incorporate this information to develop measures of risk stratification for major chronic diseases, such as cancer and Alzheimer's disease. Dr. Levine's work also involves development of systems-level outcome measures of aging, aimed at facilitating evaluation for gero-protective interventions. A number of the existing biological aging measures she has developed are being applied in both basic and observational research.

Dr. Sana Farid, MD (https://www.drsanafarid.com/) is a Surgeon, Entrepreneur, and Futurist, who strives to utilize Emerging Technologies to make the world a better place, and has been key to pushing this vision and the boundaries of innovation through her extensive research and development of impactful programs using immersive technologies like Extended Reality (XR). A driving force in the progression of these Immersive Technologies, Dr. Farid has been hailed as one of the top 100 women in XR globally due to her outstanding achievements in creating industry standards, designing implementation strategies and best practices to help organizations take advantage of what immersive technologies have to offer and develop initiatives to make the use of XR safe. Dr. Farid's major work involves helping organizations implement XR with a successful and scalable strategy and she is an avid researcher determined to use future tech solutions for societal well-being. A qualified surgeon and a distinguished ambassador of women empowerment programs in the region, she supports government and non-governmental initiatives leading them to envision, strategize and streamline AI/AR/VR based programs in various sectors, including healthcare, aviation, education and public services. Dr. Farid obtained her MBBS in Medicine & Surgery from Dow University of Health Sciences, and did a General Surgery Residency at King Hamad University Hospital in Bahrain.

Dr. Evelyne Bischof, MD  is an expert in internal medicine and oncology, with a focus on preventative and precision medicine, bio-gerontology, and geronto-oncology. Dr. Bischof is deeply passionate about next-generation medical technology, and the applications of artificial intelligence for biomedical research and practice. Dr. Bischof spent a decade practicing medicine and performing translational research in Switzerland, US, and China. Dr. Bischof is a medical doctor with an MD from Max Planck Institute for Molecular Biology and Genetics, and interned at Columbia University, Harvard MGH, and Beth Israel Medical Deaconess. Dr. Bischof is the author of over 40 peer-reviewed papers and is a frequent speaker at scientific and medical conferences. Dr. Bischof serves as Assistant Professor - Shanghai University of Medicine and Health Sciences; Associate Faculty Shanghai Jiao Tong University, and Researcher at University Hospital of Basel. In addition to those roles, Dr. Bischof is Longevity Physician at Human Longevity, Inc., Clinical Advisor, Insilico Medicine, and Scientific Advisor, Holmusk. Dr. Bischof is also Chair of the Visionary Board of The Longevity Science Foundation (https://longevity.foundation/), a new Swiss foundation committed to distributing more than $1 billion over the next ten years to research, institutions and projects advancing healthy human longevity and extending the healthy human lifespan to more than 120 years.

Mr. Larry Curley is Executive Director of The National Indian Council on Aging (https://www.nicoa.org/), a 501(c)(3) nonprofit organization founded in 1976 by members of the National Tribal Chairmen's Association who called for a national organization focused on the needs of aging American Indian and Alaska Native elders. The mission of NICOA is to advocate for improved comprehensive health, social services and economic well-being for American Indian and Alaska Native elders. Mr. Curley is a member of the Navajo Nation with over 40 years of experience working in the aging and healthcare fields. He has worked with Congress, other branches of the federal government, and national organizations on aging to develop support for programs affecting elder American Indians. After receiving his master's degree in public administration at the University of Arizona, along with a certificate in gerontology, Mr. Curley worked as a gerontological planner at an Area Agency on Aging in Pima County, Arizona, where he was instrumental in establishing a county public fiduciary program. As a lobbyist in Washington, D.C., he successfully advocated for the passage of Title VI of the Older Americans Act, an amendment which he wrote. Mr. Curley directed the Navajo Nation's Head Start program, one of the five largest Head Start programs in the country, and has served as a nursing home administrator of a tribal, long-term care facility, a hospital administrator in northern Nevada, and as a college instructor at the University of Nevada-Reno and Eastern Washington University. Mr. Curley was named as the assistant dean of the Four Corners region for the Burrell College of Osteopathic Medicine. He's also served as the public representative on the American College of Physicians Clinical Guidelines Committee, and as the director of program development for the Rehoboth McKinley Christian Health Care Services in northwest New Mexico.

Eric G. Meyer is the Founder and Director of Generation Atomic (https://generationatomic.org/), a nuclear advocacy non-profit which he founded after hearing about the promise of advanced nuclear reactors, and he decided to devote his life to saving and expanding the use of atomic energy. Eric worked as an organizer on several political, union, and issue campaigns while in graduate school for applied public policy, taking time off to attend the climate talks in Paris and sing opera about atomic energy. Eric began his full time nuclear work in May of 2016 with Environmental Progress by organizing marches, rallies, and trainings in California, New York, and Illinois, before leaving to found Generation Atomic in late 2016. In only a short period of time, Generation Atomic has made significant progress in the world of nuclear advocacy. Over the last year they've held several advocacy trainings at conferences, Marched for Science, talked to over tens of thousands voters, and carried the banner for nuclear energy at the climate talks in Morocco, Germany, and Poland. Eric attended University of Minnesota-Duluth where he obtained a Master's Degree in Advocacy and Political Leadership, with Concentrations in Public Sector and Non-profits, and a Bachelor of Arts in Music Performance.

Mr. Viren Shah is Vice President & Chief Digital Officer, at GE Appliances (GEA - https://www.geappliances.com/), the American home appliance manufacturer, now a majority owned subsidiary of the Chinese multinational home appliances company, Haier (https://www.haierappliances.com/). Mr. Shah has been with GEA since October 2018, in which time he was appointed to lead the business through a digital transformation with a focus on data/intelligence at the center of gravity. Prior to becoming part of the Haier company, Mr. Shah was the CIO at Masco Cabinetry, and CIO Council Leader for their parent company, Masco Corporation, the international conglomerate manufacturer of products for the home improvement and new home construction markets. Mr. Shah has more than 20 years of global experience in creating business value using technology with a strong focus on customers for Fortune 10 organizations, such as his decade at the Walmart organization. He has contributed as a senior leader towards the success of startups, turnarounds and global mergers and acquisitions. Mr. Shah implemented “Think Global and Act Local” methodologies, utilizing operational and cultural experience in areas of IT strategy, omnichannel, business development and governance in more than 20 countries across the Americas, Australia, Europe, Asia and Africa. Mr. Shah holds a bachelor's degree in computer science from Bombay University, a master of business administration degree in international marketing/short-term finance from the New York Institute of Technology, and an executive education certificate in digital marketing strategies for digital economy from the Wharton School.

 Dr. Volkmar Weissig, Sc.D., Ph.D. is a Tenured Full Professor of Pharmacology, Chair of the Department of Pharmaceutical Sciences, and Co-Director of the Nanomedicine Center of Excellence in Translational Cancer Research, at Midwestern University, Glendale, AZ, USA. Dr. Weissig received his B.S., M.S. and Ph.D. degrees in Chemistry, and his postdoctoral Sc.D. degree in Biochemistry and Pharmaceutical Biotechnology from the Martin-Luther University in Halle (Germany). Dr. Weissig completed several years of postdoctoral fellowships at the Cardiology Research Center in Moscow (Russia), at the Academic Department of Medicine at the Royal Free Hospital School of Medicine in London (UK), at the Institute of Organic Chemistry at the Czechoslovakian Academy of Science in Prague (CSFR), at the College of Pharmacy and the College of Medicine at the University of Florida, Gainesville, FL, and at Harvard Medical School and Massachusetts General Hospital in Boston, MA. Before joining the faculty at Midwestern University, Dr. Weissig was an Assistant Professor of Pharmaceutical Sciences at Northeastern University in Boston, MA. Dr. Weissig holds 16 patents and he has published over 100 research papers, review articles and book chapters, mostly in the area of nano drug delivery systems. He also edited and published 8 books. He serves as the Associate Editor of the Journal of Liposome Research and he is member of several other Editorial Boards. In July 2009 he was inducted into the World Technology Network as a Fellow. In October 2014 Dr. Weissig was elected Inaugural President of the World Mitochondria Society. 

Mr. Lameen Abdul-Malik is a Nobel Peace Prize recipient, Coffeepreneur, Intellectual Philanthropist, and Executive Director of Honest Management LLC, UAE. (https://www.honestmanagement.org/) Awarded the Nobel Peace Prize with the International Atomic Energy Agency (IAEA) in 2005, for which he worked for over 14 years, Mr. Abdul-Malik has over twenty years' experience in international development, primarily in Africa, where he was responsible for developing the IAEA regional strategy to help over 41 African countries use nuclear science and technology to address their primary development challenges in health, agriculture and radiation safety. Mr. Abdul-Malik started his career, working at the UK Department for International Development, where he worked on the international trade, debt relief and economic and social research. Mr. Abdul-Malik is also very passionate about coffee and has been writing about coffee for over 13 years on his blog (https://fromcoffeewithlove.com/), for which he was featured on CNN, and recently launched his own espresso brand coffee in collaboration with Sippy Beans of Dubai, UAE. In June 2019, Mr. Abdul-Malik was invited to participate at the International Coffee Organisation (ICO) and European Union (EU) Coffee Symposium on the UN Sustainable development goals (SDGS), where he interacted with global players such as Starbucks, Nestle, and Illy, as they discussed ways in which to improve the coffee value chain. Following his departure from the IAEA, Mr. Abdul-Malik worked as a director for The Future Investment Initiative Institute (FII Institute), a Riyadh, KSA based global foundation focusing on the world's brightest ideas in sustainability, healthcare, education, AI, and robotics, and helping them find their way to materialize, scale and create a positive sustainable impact on humanity. Now as Executive Director of Honest Management LLC, UAE, Mr. Abdul-Malik has set himself a goal of having a positive impact on at least one million people lives within the next 5 years, using his various skill sets in development, education and of course, in coffee. Mr. Abdul-Malik has a Master of Business Administration in International Management from University of Exeter Business School.

Dr. Antonio Giordano, MD, Ph.D., (https://www.drantoniogiordano.com/) is President and Founder of the Sbarro Health Research Organization (https://www.shro.org/), which conducts research to diagnose, treat and cure cancer, but also has diversified into research beyond oncology, into the areas of cardiovascular disease, diabetes and other chronic illnesses. Dr. Giordano is also a Professor of Molecular Biology at Temple University in Philadelphia, a 'Chiara fama' Professor in the Department of Pathology & Oncology at the University of Siena, Italy, and Director of the Sbarro Institute for Cancer Research and Molecular Medicine, and the Center for Biotechnology, at Temple's College of Science & Technology. In his research throughout the years, Dr. Giordano has identified numerous tumor suppressor genes, including Rb2/p130, which has been found to be active in lung, endometrial, brain, breast, liver and ovarian cancers, as well as interesting synergistic effects of gamma radiation in combination with this gene, accelerating the death of tumor cells. Dr. Giordano went on to discover Cyclin A, Cdk9 (which is known to play critical roles in HIV transcriptions, inception of tumors, and cell differentiation), and Cdk10. Dr. Giordano also developed patented technologies for diagnosing cancer. Dr. Giordano has published over 400 papers on gene therapy, cell cycle, genetics of cancer, and epidemiology. In 2011, Dr. Giordano and his team uncovered anti-tumor agents that might be effective in the treatment of mesothelioma, a cancer caused by prolonged asbestos exposure, by inducing cell death without harming healthy cells. Dr. Giordano has been involved with many other fascinating programs, including digital health work to see if watching a computer animated avatar could assist women to lose weight, as well as analyzing the environmental relationship among toxic dumping and cancer growth, birth defects, and CNS disorders, due to the Camorra (the Neapolitan Mafia) illegally disposing of toxic waste.

Dr. Jean C. Accius, PhD, is Senior Vice President, AARP Global Thought Leadership (https://www.aarp.org/). Dr. Accius leads a team in positioning AARP (formerly known as the American Association of Retired Persons) as a global thought leader, identifying emerging trends around the world, cultivating and elevating new ideas, forging global strategic alliances that become the foundation for collaboration and sparking bold solutions to change systems and improve the lives of the global population as it ages. Dr. Accius is a passionate champion and catalyst for changing how the world sees and values aging. He is an internationally recognized thought leader on aging, longevity, equity, health systems transformation and modernizing the delivery and financing of long-term care. With tri-sector experience and deep knowledge, he has a strong track record of building high-performing teams, managing cross-functional operations and processes, and developing innovative and actionable solutions, policies, and programs to close the opportunity gap so that everyone can live longer, healthier and more productive lives. A highly sought after author and speaker, Dr. Accius has been quoted by or appeared in numerous media outlets, including The New York Times, Forbes, TIME Magazine, USA Today, Reuters, Politico, Next Avenue, ESPN's Undefeated, Rolling Out, NationSwell, Congressional Quarterly, and Huffington Post. In 2020, he facilitated several sessions at the 50th annual World Economic Forum in Davos, Switzerland and also engaged nearly 300 leaders across industries and sectors, including 20 ambassadors and many delegates, at the United Nations. Dr. Accius is a member of the National Association of Corporate Directors and has held a variety of board and advisory positions including Justice in Aging, the American Society on Aging, Leadership Maryland and the American University School of Public Affairs Board of Advisors. Dr. Accius is an Executive Leadership Council Fellow, member of G100's Transformational Leadership Network, and holds a bachelor's degree in hospitality administration and a master's degree in aging studies from the Claude Pepper Institute at Florida State University. He also holds a Ph.D. in public administration from American University. Dr. Accius is a graduate of Leadership Maryland's Class of 2014, the Harvard T.H. Chan School of Public Health program on health reform, and Stanford University's Graduate School of Business Corporate Innovation program.

 The Chernobyl disaster / nuclear accident, occurred on April 26th, 1986, at the No. 4 reactor in the Chernobyl Nuclear Power Plant, near the city of Pripyat in the north of Ukraine. The initial emergency response, together with later decontamination of the environment, ultimately involved more than 500,000 personnel and cost an estimated US$68 billion, adjusted for inflation. The current Chernobyl Exclusion Zone covers an area of approximately 2,600 km2 (1,000 sq mi) in Ukraine, immediately surrounding the Chernobyl Nuclear Power Plant, where radioactive contamination is highest and public access and inhabitation are restricted. The Exclusion Zone's purpose is to restrict access to hazardous areas, reduce the further spread of radiological contamination, and conduct radiological and ecological monitoring activities. Today, the Exclusion Zone is still one of the most radioactively contaminated areas in the world and draws significant scientific interest for the high levels of radiation exposure in the environment, as well as increasing interest from tourists. Despite the extremely high radioactivity of the region, the zone has become a thriving sanctuary with natural flora and fauna with some of the highest biodiversity and thickest forests in all of Ukraine. On this episode of our show, we are joined by Mykola Tolmachov, of the Chernobyl-51 Industrial Cluster, discussing their novel public-private partnership for both ecosystem restoration and the production of both energy and chemical byproducts, in the exclusion zone. English translation during the episode is performed by Ms. Victoria Laskina-Ustimenko. 

Giovanni (Gio) Battistini, is Managing Director at the innovation venture company, Better Gambit LLC (https://www.bettergambit.com/). Gio is passionate about strategic and entrepreneurial innovation-driven business opportunities and has expertise in business development, strategic alliances, strategic investments, product development and commercialization, in both early stage startups and global corporations. Most recently, Gio served as Senior Vice President of the Ferrero company's Open Innovation Science, a global organization with the mission of driving the discovery, evaluation and integration of external science, technology and entrepreneurial innovations relevant to Ferrero (the Italian manufacturer of branded chocolate and confectionery products, and the second biggest chocolate producer and confectionery company in the world.) Prior to joining Ferrero, Gio was Global Vice President of Flavor Innovation Discovery at Firmenich, where he led the strategic discovery and commercialization of scientific innovations in the areas of taste modulation, health & nutrition, natural & sustainable, and breakthrough cost innovation. Prior to joining Firmenich, Gio was the co-founder and CEO of Zonebee, a spin-off from the University of Arizona, where he led a multi-disciplinary R&D team to create visionary technology to support informal learning and knowledge management. Gio has more than 25 years of experience in managing and taking to market innovative technology in several industries, both in Global 500 companies and early stage startups. Gio serves also as Strategic Advisor, Enzymit; Venture Advisor, Sofinnova Partners; and Alliance Partner, Green Swan Partners. Gio started his career at ABB Ltd, the Swedish–Swiss multinational corporation headquartered in Zürich, Switzerland, operating mainly in robotics, power, heavy electrical equipment, and automation technology areas. Gio has a MS in Electronic Engineering from Università di Pavia.

 Dr. Arathi Sethumadhavan, Ph.D. is Head of User Research for AI, Ethics & Society, at Microsoft's Cloud+AI organization, where she works at the intersection of user research, ethics, and product experience. In her current role, Dr. Sethumadhavan is focused on the Microsoft AI ethical principles (privacy and consent, fairness, inclusion, accountability, and transparency) as it relates to various Microsoft AI experiences. Dr. Sethumadhavan is a seasoned research leader, with two decades of experience studying human-technology interaction, and during the course of her career, she has led user research for several novel and complex applications (e.g., Microsoft's custom neural voice, facial recognition), as well as at Medtronic, where she provided human factors leadership to multiple products in the Cardiac Rhythm and Heart Failure portfolio, including the world's smallest pacemaker. She has also spent several years investigating the implications of automation on air traffic controller performance and situation awareness. Dr. Sethumadhavan is also a Fellow at the World Economic Forum, where she is working on unlocking opportunities for positive impact with AI to address the needs of the aging population. Dr. Sethumadhavan has published ~60 articles on a range of topics from patient safety, affective computing, and human-robot interaction, has delivered ~80 lectures, has been cited by the American Psychological Association and the Economist, and has worn many hats along the way, including research leader, strategist, author, mentor, editor, keynote speaker, and sometimes adjunct professor. Dr. Sethumadhavan's book, "Design for Health: Applications of Human Factors", was published in 2020. Dr. Sethumadhavan has a PhD in Experimental Psychology (specialization in human factors and ergonomics) from Texas Tech University and an undergraduate degree in Computer Science University of Calicut. 

Kimberly A. Reed just finished up a 2-year term as President and Chairman of the Board of Directors of the Export- Import Bank of the United States (EXIM - https://www.exim.gov). She was the first woman to lead EXIM in the agency's 87-year history, was the first recipient of EXIM's highest honor, the Franklin D. Roosevelt Award, and was confirmed by the U.S. Senate in 2019 on a strong bi-partisan basis. EXIM provides loans, guarantees, and export credit insurance for the export of U.S. goods and services from enterprises ranging from Fortune 100 companies to small businesses in a multitude of sectors including infrastructure, power, agriculture, transportation/aviation, health care, commodities, industrial, and technology. Ms. Reed was recognized for successfully navigating Congress to re-open EXIM after four years of dormancy and transforming the mission and impact of the 515-person independent federal agency. Ms. Reed also spearheaded EXIM's historic, longest-ever Congressional re-authorization of seven years and a significant new mandate, the Program on China and Transformational Exports, which focuses on industries including biomedical sciences, biotechnology, wireless communication (5G), renewable energy, financial technologies, artificial intelligence, and the space industry. Prior to EXIM, Ms. Reed spent her career working at senior levels in both the public and private sectors. Ms. Reed served as President of the International Food Information Council (IFIC) Foundation where she worked with multi-national food, agriculture, and nutrition companies to understand consumer insights, communicate the science, and increase U.S. sales and exports. At the U.S. Department of the Treasury, Ms. Reed headed the Community Development Financial Institutions Fund, where she oversaw the award of $4 billion in tax credits, loans, and grants to financial institutions and economic development groups investing in distressed communities across the nation. Ms. Reed also served as Senior Advisor to U.S. Treasury Secretaries John Snow and Henry Paulson, as well as counsel to three committees in the U.S. House of Representatives—Ways and Means, Government Reform and Oversight, and Education and the Workforce Committees, where she focused on Congressional investigations, oversight, and reform of federal agencies. She was also Vice President for Financial Markets Policy at Lehman Brothers in New York. Recognized as one of the “100 Women Leaders in STEM,” Washingtonian's “Most Powerful Women in Washington,” and West Virginia Executive's “Lawyers and Leaders,“ Ms. Reed previously served on the Boards of the Alzheimer's Association, Alzheimer's Impact Movement, American Swiss Foundation, National Coalition for Food and Agriculture Research, Tax Coalition, and West Virginia Wesleyan College. She was the first woman elected as Chair of the Republican National Lawyers Association and is a life member of the Council on Foreign Relations. Ms. Reed earned her J.D. from West Virginia University College of Law and B.S. in biology from West Virginia Wesleyan College. She is a Certified Association Executive (CAE), earned a Professional Certificate in Finance from the New York Institute of Finance, and, with a passion for travel, she has visited more than one hundred countries.

Dr. Maria Elena Bottazzi  is Distinguished Professor of Biology, Associate Dean of the National School of Tropical Medicine, and Professor in the Departments of Pediatrics, Molecular Virology and Microbiology, Integrative Molecular and Biomedical Sciences, and Translational Biology and Molecular Medicine, at Baylor College of Medicine. Dr. Bottazzi is also Co-Director, Texas Children's Hospital Center for Vaccine Development, Adjunct Professor, Department of Bioengineering, Rice University, and Editor-in-Chief, Current Tropical Medicine Reports. Dr. Botazzi has a degree in microbiology from Universidad Nacional Autónoma de Honduras, a PhD from University Of Florida, did a Post-Doctoral Fellowship at University Of Pennsylvania and at University Of Miami Hospital And Clinics, and a Fellowship at American Association for the Advancement of Science Leshner Leadership Institute. Dr. Botazzi is involved in a range of activities related to the development of novel vaccines and adjuvants for neglected tropical diseases (Chagas Disease, Leishmaniasis, Human Hookworm Vaccine, Schistosomiasis Vaccine), as well as extensive work on Covid vaccines.

Khaliya (https://www.khaliya.net/) is a Columbia University-trained public health specialist and Harvard University-trained specialist in Global Mental Health and Refugee Trauma. She is also a Venture Partner for Gender Equity Diversity Investments (www.gedi.vc), a new female-led VC firm targeting high growth investments that deliver top-quartile returns and measurable impact towards the UN Sustainable Development Goals with a preliminary focus on health. Formerly an aid worker in over 32 countries and a former Peace Corps Volunteer for the US State Department, she has won numerous awards for her international service. Khaliya was the youngest member of the WEF's Futures Council on the Future of Health and Healthcare and her opinion pieces have run in the New York Times (International and Domestic Editions) as well as WiredUK. Currently at work on a book on the future of mental health, Khaliya continues to be a sought after public speaker, having spoken at the Obama White House organized United States of Women Summit, the World Economic Forum's Family Business Summit, the Vatican, Clinton Global Initiative, WiredHealth, WebSummit and at the United Nations General Assembly, among others. Khaliya is next scheduled to speak at the G20 Women's Summit in Milan, Italy, and the Ethical Assembly Summit in Lisbon, Portugal, both taking place in October, 2021.

Dr. Marina Ezcurra (https://marinaezcurralab.com/) is a Lecturer in the Biology of Aging, and NeuroBiology, at the School of BioSciences, at the University of Kent, UK (https://www.kent.ac.uk/biosciences/pe...). Dr. Ezcurra received her PhD from the Karolinska Institute in 2011. Her PhD research was a collaborative project between Karolinska and the Medical Research Council Laboratory of Molecular Biology at Cambridge, where she studied neural circuits and behavior using C. elegans in the lab of Dr. Bill Schafer. During her PhD, Dr. Ezcurra identified extra-synaptic mechanisms by which nutritional status modulates nociception, involving neuro-peptidergic and dopaminergic signaling. She went on to do a postdoc working on aging with Dr. David Gems at University College London. During her postdoc, Dr. Ezcurra developed methods to monitor the development of multiple age-related diseases in-vivo in C. elegans, leading to the discovery of a previously unknown process, Intestinal Biomass Conversion. This mechanism enables the C. elegans intestine to be broken down to produce vast amounts of yolk, resulting in poly-morbidity and mortality in aging nematodes. This work illustrates how aging and age-related diseases can be the result of run-on of wild-type gene function, rather than stochastic molecular damage. Current research in Dr. Ezcurra's group focuses on how host-microbiome interactions affect host aging, and is funded by The Wellcome Trust and Royal Society. Dr. Ezcurra is a trustee board member of The British Society of Research on Aging.

Dr. Jennifer Garrison, PhD (http://garrisonlab.com/) is Assistant Professor, Buck Institute for Research on Aging, Founder & Faculty Director, Global Consortium for Reproductive Longevity & Equality (https://www.buckinstitute.org/gcrle/), Assistant Professor in Residence, Cellular and Molecular Pharmacology, UCSF and Adjunct Assistant Professor of Gerontology, USC Leonard Davis School of Gerontology. Dr. Garrison's lab is interested in understanding how neuropeptides (a large class of signaling molecules which are secreted from neurons and transmit messages within the brain and across the nervous system) regulate changes in normal and aging animals as well in understanding how they control behavior at both the cell biological and neural circuit level. Dr. Garrison received her PhD from the University of California San Francisco in Chemistry and Chemical Biology in the laboratory of Dr. Jack Taunton, where she discovered the molecular target of a natural product and elucidated a novel mechanism by which small molecules can regulate protein biogenesis. As a postdoctoral fellow in Dr. Cori Bargmann's lab at the Rockefeller University, she showed that the nematode C. elegans produces a neuropeptide that is an evolutionary precursor of the mammalian peptides vasopressin and oxytocin, and mapped a neural circuit by which this molecule, nematocin, modulates mating behavior. Dr. Garrison was named an Alfred P. Sloan Research Fellow and received a Glenn Foundation Award for Research in Biological Mechanisms of Aging in 2014, and a Next Generation Leader at the Allen Institute for Brain Science in 2015. Her work is funded by the NIH National Institute of General Medical Sciences, the Glenn Foundation for Medical Research, the Alfred P. Sloan Foundation, and the Larry L. Hillblom Foundation.

Professor Johnjoe McFadden (https://johnjoemcfadden.co.uk/) is Professor of Molecular Genetics at the University of Surrey, United Kingdom. With a Ph.D. in Biochemistry, Professor McFadden has spent many years doing in-depth research in the area of microbial genetics, including the study of the agents tuberculosis and meningitis and invented important diagnostic tests for such agents. Professor McFadden has published more than 100 scientific articles on a wide range of subjects including bacterial genetics, tuberculosis, idiopathic diseases and computer modelling of evolution, while along the way editing a book on the genetics of mycobacteria, "Systems Biology of Tuberculosis". Professor McFadden has been instrumental in creating new models of human consciousness, such as his Conscious Electromagnetic Information Field (or CEMI Theory), as well as pioneering in such cutting edge fields as Quantum Biology. Professor McFadden has lectured extensively in the UK, Europe, the USA and Japan and his work has been featured in numerous radio, television and national newspaper articles. Professor McFadden has also become a prolific author of books, including "Quantum Evolution, Life in the Multiverse" and "Life on the Edge: The Coming Age of Quantum Biology". Hi new book in entitled "Life Is Simple: How Occam's Razor Set Science Free and Shapes the Universe".

 Mr. Craig Fugate is the former Director of the Florida Division of Emergency Management, and former administrator of the Federal Emergency Management Agency (FEMA - an agency of the United States Department of Homeland Security, whose primary purpose is to coordinate the response to disasters that have occurred in the United States and that overwhelm the resources of local and state authorities.) Mr. Fugate is currently the Chief Emergency Management Officer of One Concern, (a Resilience-as-a-Service solutions company that brings disaster science together with machine learning for better decision making). Mr. Fugate is also senior advisor at BlueDot Strategies, where he assists a range of clients with emergency management implementation strategies and crisis communications. Mr. Fugate serves on the Board of Directors of PG&E Corp., one of the largest electric and natural gas utilities in the U.S., and on the staff at Indian River State College, serving as a strategic consultant in emergency management. Mr. Fugate has decades of experience at the local, state, and federal levels in disaster preparedness and management. He has also overseen preparation and response efforts for disasters such as wildfires and hurricanes, health crises, and national security threats. As Florida Director for the Emergency Management Division, Mr. Fugate oversaw the "Big 4 of '2004" (Hurricanes Charley, Frances, Ivan, and Jeanne) and as the Administrator for the Federal Emergency Management Agency, he organized recovery efforts for a record of eighty-seven disasters in 2011. 

Dr. Sonia Grego, Ph.D. is Associate Research Professor in the Department of Electrical and Computer Engineering, at Duke University (https://ece.duke.edu/faculty/sonia-grego). Dr. Grego is also the Founding Director of the Duke Smart Toilet Lab (https://smarttoilet.pratt.duke.edu/), dedicated to the opportunities that data-rich human excreta offer to improve individual and public health. The objective of the organization is to empower individuals and groups in communal living with health information for early warning of disease, health and wellness, and management of chronic diseases through wastewater analysis, without any changes of daily habits. Dr. Grego is passionate about the opportunities that advanced sanitation technologies offer to improve global health and to provide a paradigm shift in health screening both for individuals and for communities. A major project of Dr. Grego's research portfolio over the past 5 years, she has led the field testing of 10+ onsite sanitation technology prototypes from multiple organizations in international settings. She has managed year long deployments of sophisticated chemo-mechanical systems with electronic monitoring connected to wastewater pipes of buildings, ensuring no disruption of service to users while evaluating the treatment process performance. Dr. Grego has an M.S. from Università di Pisa (Italy) and a Ph.D. from University of Copenhagen (Denmark). Dr. Grego has also founded Coprata Inc. (https://coprata.com/) to commercialize technologies developed at Duke University, to detect or manage acute and chronic gastrointestinal diseases, provide early warning of infectious disease and monitor personalized wellness.

Dr. Ola Engkvist is Head of Molecular AI in Discovery Sciences, AstraZeneca R&D (https://www.astrazeneca.com/) . Dr. Engkvist did his PhD in computational chemistry at Lund University followed by a postdoc at Cambridge University. After working for two biotech companies Dr. Engkvist joined AstraZeneca in 2004. He currently leads the Molecular AI department, where the focus is to develop novel methods for ML/AI in drug design , productionalize the methods and apply the methods to AstraZeneca's small molecules drug discovery portfolio. Dr. Engkvist's main research interests are deep learning based molecular de novo design, synthetic route prediction and large scale molecular property predictions, and he has published over 100 peer-reviewed scientific publications. Dr. Engkvist is also adjunct professor in machine learning and AI for drug design at Chalmers University of Technology and a trustee of Cambridge Crystallographic Data Center.

Dr. Brian Keating, Ph.D. (https://briankeating.com/) is Chancellor's Distinguished Professor of Physics, at the Center for Astrophysics & Space Sciences (CASS), in the Department of Physics, at the University of California, San Diego . Dr. Keating is a public speaker, inventor, and an expert in the study of the universe's oldest light, the cosmic microwave background (CMB), using it to learn not just about the origins and evolution of the universe, but to gain potential insights into an even bigger picture, that of the "multiverse", a hypothetical group of multiple universes that comprise everything that exists: the entirety of space, time, matter, energy, information, and the physical laws and constants that describe them. Dr. Keating is also a writer, the best-selling author of one of Amazon Editors' Best Non-fiction Books of All Time, "Losing the Nobel Prize", and his new book is entitled "Into The Impossible: Think Like A Nobel Prize Winner". Dr. Keating is also a prolific podcaster on the Into The Impossible podcast (https://briankeating.com/podcast.php). Dr. Keating has his B.S. in Physics from Case Western Reserve University, his M.S and Ph.D. in Physics from Brown University, was a Physics Postdoctoral Scholar at Stanford University, and was an NSF Postdoctoral Fellow from California Institute of Technology. Please buy a a copy of Brian's new book, Think Like a Nobel Prize Winner, only $0.99 through 10/5/2021 - https://urlgeni.us/amzn/TLANPW

Around 2 billion people worldwide still lack access to the basic tools of improved sanitation (toilets and latrines). One billion people still have to defecate in the open, and at least 10% of the world's population is thought to consume food irrigated by raw wastewater. An estimated 800,000 children, younger than 5 years of age, perish from diarrhea each year, including conditions related to cholera, dysentery, hepatitis A, typhoid and polio. Mr. Jack Sim is the Founder of the World Toilet Organization (https://www.worldtoilet.org/), an organization established with the aim to break the taboo around toilets and this global sanitation crisis. Mr. Sim is also the founder of the Restroom Association of Singapore, the World Toilet Day initiative, and Bottom of the Pyramid (BOP) Hub. In 2001, for "creating good will and bringing the subject into the open" and "mobilizing national support in providing on-the-ground expertise", Mr. Sim received the Schwab Foundation award for Social Entrepreneur of the Year. In 2004, he was awarded the Singapore Green Plan Award 2012 by Singapore's National Environment Agency (NEA) for his contribution to Environment. In 2006, he was invited to launch The German Toilet Organization in Berlin. He is also a founding member of American Restroom Association. In 2007, Mr. Sim became one of the key members to convene the Sustainable Sanitation Alliance (SuSanA) comprised of over 130 organizations active in the sanitation sector. He is also an Ashoka Global Fellow and in 2008 was named Hero of the Environment by Time Magazine. Mr. Sim also sits in the World Economic Forum's Global Agenda Councils (GAC) for Water Security and also the GAC for Social Entrepreneurship. Mr. Sim graduated with a Masters in Public Administration from the Lee Kuan Yew School of Public Policy in 2013. He was shortlisted for the Sarphati Sanitation Award in November 2013. Mr. Sim also founded the BOP HUB and a series of social businesses and startups. He is now constructing a 65,000 sq ft World Trade Center for the Poor in Singapore to coordinate an effort to transform the 4 billion poor into a massively efficient marketplace to end global poverty.

 Dr. Dina Radenkovic, MD, is an academic doctor and medical technology entrepreneur, working in the field of the computational biology of aging. Dr. Radenkovic is also a Partner at the SALT Bio-Fund, and a co-founder of Hooke, an elite longevity research clinic in London. Dr. Radenkovic has a dual degree in medicine and physiology from University College London Medical School, and did her residency at St Thomas' Hospital in London. She later worked as Research Fellow at King's College London and at Harvard University. Dr. Radenkovic has led a variety of projects, including a digital therapeutics company for women and an algorithm for cardiac MRI based on fractal geometry, to major industry acquisitions. Dr. Radenkovic has over 30 academic papers, 7 grants, and over 40 scientific conference presentations. She is fluent in 5 languages and 3 programming languages. 

In dieser Podcastepisode stellt sich Ira Pastor und sein Unternehmen "Bioquark" einer wirklich interessanten Frage: Werden wir den Tod überwinden?Ihre Arbeit konzentriert sich dabei auf die sogenannten 3 R's – Regeneration, Reversion von Krankheiten und Revitalisierung/Verjüngung bei altersbedingten Leiden – mit dem Ziel, eine bessere Zukunft für die Menschen zu ermöglichen. Komplexe Organregeneration, der Übergang von Krebs in eine Reihe von harmlos beherrschbaren Krankheiten und die Verwischung der Grenzen zwischen Leben und Tod – das alles sind für Ira Pastor keine bloßen Ideen mehr, sondern nahe Zukunft. Doch komplexe biologische Mechanismen erfordern viel mehr bio-pharmazeutische Interventionen.In seiner Rede betont er deshalb, wie viel Potential und Wissen in der Natur zu finden sind. Ira Pastor zeigt auf, dass neuere Forschungen vor diesem Hintergrund bereits völlig neue Wege beleuchten, wie nicht-menschliche Bioprodukte positiv auf die Gesundheit und das Wohlbefinden der Menschen einwirken können. So könnte die Umkehrung des Todes ein Ereignis sein, das uns noch vor der Umkehrung des menschlichen Alterns vor Augen geführt werden wird.______________________________________Wenn du mehr erfahren willst, besuche auch meine Website: https://janszky.de/?p und abonniere diesen Kanal.Hier geht's zum 2b AHEAD Zukunftskongress: https://zukunftskongress.2bahead.com/?pWerde zum Future-Me Member: https://janszky.de/futureme_membership?pSichere Dir jetzt Dein Geschenk auf: https://janszky.de/geschenk?p

Richard welcomes the CEO of a life sciences firm to discuss his efforts to dramatically extend the human life span, including the possible health benefits of mosquito bites.   GUEST:  Ira Pastor is the CEO of Bioquark a life sciences company, developing proprietary combinatorial biologics for the regeneration and repair of human organs and tissues. Ian has over 30 years of experience across multiple sectors of the pharmaceutical industry including pharmaceutical commercialization, biotech drug development, managed care,  and distribution.  Ira is a member of the World Economic Forum's Human Enhancement council.

Many other organisms have superhuman abilities, such as the capacity to ward off cancer, periodically reverse aging, regenerate limbs, and even regrow brains. Yet these non-human species share many genetic similarities with us. This naturally raises the question of whether we can learn from other animals in our quest to delay aging, reverse disease, and – dare I say it – return to life from the empty expanse of death. These lofty goals bring us to today's episode of humanOS radio in which Dan speaks with Ira Pastor, CEO of Bioquark.

Fernando Aires guest hosts this edition of the Holistic Survival Show, and talks with Ira Pastor, CEO of Bioquark. He's been in the pharmaceutical industry for 30+ years in a wide variety of positions. Before joining Bioquark, Ira served as VP of Business Development for the Phytomedics Inc., bringing in $40 million of private equity and over $50 million of licensing deals. Ira and Fernando discuss Bioquark's current investigation into making our bodies regenerate like other organisms, in order to avoid all the trouble that can be created by introducing foreign bodies into our ecosystem. Key Takeaways: [2:32] How Bioquark works [4:38] Why humans aren't able to regenerate parts like "lower" organisms [9:59] What triggers in the body cause regeneration to start? [12:38] If Bioquark is tapping into our youthful regeneration to make our bodies heal faster [16:57] The types of problems Bioquark is designed to solve [20:36] How is it possible to bring people back from the dead? [24:11] If they are currently doing any clinical research for recovering braindead patients [28:49] Where the money for their research and development is coming from [29:15] The biggest challenges facing Bioquark's work Website: www.bioquark.com www.reanima.tech www.regenerage.clinic